Image

The Role of Intestinal Microbiota Dysbiosis in the Development of Spondyloarthritis

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

The primary objective of this case-control study aims to explore the role of bacterium Ruminococcus gnavus (R. gnavus) with intestinal biopsy and faecal sampling in the initiation and the development of spondyloarthritis (SPA) in comparison with health control subjets (patients without chronic disease but have indication to digestive endoscopy).

Description

As secondary objectives, the study aims:

  • to research the abundance of bacterial strain of R. gnavus in mucosal sampling by biopsy;
  • to study the interaction between R. gnavus bacterium and mucus from histological sampling;
  • to correlate the expression of genes of intestinal mucus with the variations of identified microbiota of mucus biopsy;
  • to study the interaction between bacteria and intestinal epithelial cells during culture;
  • to demonstrate perturbations of the immune responses by dysbiosis.

Eligibility

Inclusion Criteria:

Patients with SPA:

  • Patients ⩾ 18 years;
  • Diagnosed as spondyloarthritis (SpA) according ASAS classification;
  • Affiliated to a social security scheme;
  • Have signed the written informed consent form.

Control subjects:

  • Subjects ⩾ 18 years;
  • Subjects free of SPA and planned for a digestive endoscopy for another indication such as to explore the risk of colorectal cancer in family member;
  • Affiliated to a social security scheme;
  • Have signed the written informed consent form.

Exclusion Criteria:

  • Subjects unable to understand the proposed study and/or sign a informed consent form;
  • Pregnant women or breast feeding women;
  • Subjects under guardianship or curatorship;
  • Have taken antibiotic 1 month prior to inclusion;
  • Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome;
  • Refusal of subjects to participate to the study;
  • Foreign patients under french AME scheme.

Study details

Spondyloarthritis, Ruminococcus Gnavus

NCT04853212

Assistance Publique - Hôpitaux de Paris

20 March 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.